Indoco Remedies Share Price Gains 5% After USFDA Clears Patalganga API Unit

Indoco Remedies share price (NSE: INDOCO) climbed almost 5% on the BSE, touching an intra-day high of ₹251.05. The stock saw strong buying interest after the company received an Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility at Patalganga.

Indoco Remedies Share Price Movement

At 10:15 AM, the stock was trading slightly higher at ₹242.55 on the BSE, while the benchmark Sensex was up 0.44%. The company’s current market cap stands at ₹2,237 crore. The stock has a 52-week high of ₹348.6 and a low of ₹190.

Details of the EIR

The USFDA issued the EIR after conducting an inspection at the Patalganga facility between September 15 and 19, 2025. The report confirms that the plant meets the agency's regulatory and quality requirements.

Managing Director Aditi Panandikar said the approval reinforces the company’s commitment to high-quality standards and trusted healthcare solutions.

What Is an EIR and Why It Matters

An EIR is a detailed report issued by the USFDA after inspecting a drug manufacturing facility. It includes the inspection scope, findings, observations, and conclusions.
It provides deeper clarity than Form 483 and is closely watched by pharma companies and investors because it influences product approvals, compliance status, and stock sentiment.

Also Read: Best Gold Mutual Funds in India for Dec 2025!

About Indoco Remedies

Indoco Remedies is a fully integrated pharma company with 7 decades of presence in India. It manufactures both formulations and APIs and exports to 55 countries. The company operates 11 manufacturing facilities, seven for finished dosages and four for APIs—supported by an R&D centre in Navi Mumbai and a clinical research unit in Hyderabad. Its plants meet global regulatory standards, including approvals from USFDA, UK-MHRA, TGA, SAHPRA, and several other international agencies.

Conclusion

Indoco Remedies’ share price received a strong boost after the USFDA issued a positive EIR for its Patalganga API plant. The approval strengthens the company’s compliance track record and reinforces investor confidence in its manufacturing quality and global market readiness.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.